Are you Dr. Srivastava?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 79 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
818 Forest LN
Waterford, WI 53185Phone+1 262-514-3700Fax+1 262-514-3867
Summary
- Dr. Alok Srivastava, MD is a board certified internist in Waterford, Wisconsin. He is currently licensed to practice medicine in Wisconsin, Illinois, and Ohio. He is affiliated with Aurora Medical Center Burlington.
Education & Training
Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 1995 - 1998
University of Cincinnati College of MedicineClass of 1995
Certifications & Licensure
WI State Medical License 1996 - 2025
OH State Medical License 2001 - 2010
IL State Medical License 2006 - 2008- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2010-2013
- Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2010-2013
Clinical Trials
- Musculoskeletal Function in Hemophilia Start of enrollment: 2004 Jun 01
Publications & Presentations
PubMed
- Lower-dose emicizumab prophylaxis: can less be more?Alok Srivastava, Alfonso Iorio
Journal of Thrombosis and Haemostasis. 2024-04-01 - Early detection, reactivation of cytomegalovirus DNA & immediate early (IE)-mRNA expression in hematopoietic stem cell-transplant patients.Sangeeta Thomas, Santhosh Kumar Duraisamy, Rayaz Ahmed, Aby Abraham, Auro Vishwabandhya
Indian Journal of Medical Microbiology. 2023-12-19 - 17 citationsFitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.Alok Srivastava, Savita Rangarajan, Kaan Kavakli, Robert Klamroth, Gili Kenet
The Lancet. Haematology. 2023-05-01
Press Mentions
Fitusiran Beneficial in Hemophilia a, B with or Without InhibitorsMarch 31st, 2023- Monthly Injections Might Lower Bleeding in People with HemophiliaMarch 31st, 2023
- Bhubaneswar Hosts Conference on Endoscopic SurgerySeptember 25th, 2022
- Join now to see all
